Resources for Antibody Therapeutics Purification

Select document type:

Unlock the potential of next-generation antibody therapeutics

Let us help you optimize your downstream process for your next-generation antibody therapeutics. Explore valuable insights into the use of our affinity chromatography resins, which have been specifically developed to address the challenges associated with engineered monoclonal antibodies.

Find your resin using the 3D antibody purification tour

Seeking to streamline your bispecifics purification process?

Watch our webinar, "Optimizing Bispecifics Antibody Purification: Case Studies and Strategies" to explore innovative capture and polish techniques to support clinical and commercial applications.

Top trending content

Webinar: Accelerating mAb Process Development in the Growing Therapeutics Market

Learn how to boost the efficiency of monoclonal antibodies (mAbs) development through optimized CHO cell line creation, media selection, and high-throughput downstream screening.
 

Webinar: Advances in Flow-Through Technology to Enhance mAbs Polishing

Explore three case studies that demonstrate how advanced chromatographic tools can enhance the purification of complex therapeutics by reducing aggregates, host cell proteins (HCPs), and retroviruses.

eBook: Purification techniques for next-generation antibody therapeutics

Read about developments in the purification and polishing of monoclonal therapeutic using mixed-mode and hydrophobic interaction resins.

eBook: Advances in Downstream Processing of Complex Antibodies

Examine the benefits of affinity chromatography for the purification of novel biologics through several case studies.
 

Free webinar resources

Free educational resources

  Asset type Title Description
Article Overcoming Purification Challenges in Antibody Therapeutics Manufacturing with Subdomain-Specific Affinity Solution Discover resins—developed to bind antibody subdomain regions—that can help support the downstream process for a variety of antibody formats.
Article Overcoming Purification Challenges in Antibody Therapeutics Manufacturing Overcome the purification challenges presented by complex novel formats derived from conventional antibody structures, including Fab fragments, Fc-fusion proteins, and bispecifics.
eBook Antibody Therapeutic Polishing: Utility of Hydrophobic-Interaction Chromatography Explore innovative POROS HIC resins with novel chemistries for effective aggregate and viral clearance in challenging monoclonal antibody (mAb) drugs.

eBook Efficient Techniques for Antibody Therapeutic Purification Learn about innovative purification tools to help maximize the productivity of downstream processing of traditional and complex antibody therapeutics.
eBook Quality Innovation in Monoclonal Antibody Manufacturing Discover solutions for common purification, analysis, and quality evaluation challenges when manufacturing modern antibody-derived therapies.
Infographic Resolving 5 Challenges of Novel mAb Purification Provides insights into eliminating common issues in the purification of modified mAb conformations.
Poster Upgrade Monoclonal Antibody Purification Workflow with a New Source of Protein A Resin Review the application data of our new Protein A resin, designed to help improve the productivity and efficiency of your antibody purification process.
Poster Accelerating Antibody Drug Development with Subdomain-Specific Affinity Chromatography Explore application data of our subdomain-specific affinity portfolio developed to address purification challenges with novel antibody molecules.
Poster POROS Benzyl Ultra Viral Clearance and Impurity Removal for a Novel Antibody Format Used in an Enhanced Antibody Drug Conjugate Gain knowledge on the use of a hydrophobic interaction resin in the reduction of HMW species that are challenging to remove through standard bind and elute cation exchange chromatography.

Discover purification solutions for antibody therapeutics

We have developed an innovative portfolio of affinity chromatography resins to help you solve challenges in the downstream process of next-generation antibody therapeutics. These resins are specifically designed for the purification of engineered monoclonal antibody (mAbs) modalities.


 

For research use or further manufacturing. Not for diagnostic use or direct administration into humans or animals.